Real-world experience with capmatinib in MET exon 14-mutated non-small cell lung cancer (RECAP): a retrospective analysis from an early access program

BACKGROUND: Patients with non-small cell lung cancer (NSCLC) presenting with mesenchymal–epithelial transition (MET) exon 14 skipping mutation have an unfavorable prognosis with standard treatments. Capmatinib is a selective MET inhibitor, which showed promising efficacy in this patient population i...

Descripción completa

Detalles Bibliográficos
Autores principales: Illini, Oliver, Fabikan, Hannah, Swalduz, Aurélie, Vikström, Anders, Krenbek, Dagmar, Schumacher, Michael, Dudnik, Elizabeth, Studnicka, Michael, Öhman, Ronny, Wurm, Robert, Wannesson, Luciano, Peled, Nir, Kian, Waleed, Bar, Jair, Daher, Sameh, Addeo, Alfredo, Rotem, Ofer, Pall, Georg, Zer, Alona, Saad, Akram, Cufer, Tanja, Sorotsky, Hadas Gantz, Hashemi, Sayed M. S., Mohorcic, Katja, Stoff, Ronen, Rovitsky, Yulia, Keren-Rosenberg, Shoshana, Winder, Thomas, Weinlinger, Christoph, Valipour, Arschang, Hochmair, Maximilian J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9201318/
https://www.ncbi.nlm.nih.gov/pubmed/35720834
http://dx.doi.org/10.1177/17588359221103206

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9201318/
https://www.ncbi.nlm.nih.gov/pubmed/35720834
http://dx.doi.org/10.1177/17588359221103206

Ejemplares similares